Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
Research reports from D.M. Skowronski and co-authors provide new insights into flu vaccines
February 18th, 2009
"Trivalent inactivated influenza vaccine (TIV) is reformulated annually to contain representative strains of 2 influenza A subtypes (H1N1 and H3N2) and 1 B lineage ( Yamagata or Victoria). We describe a sentinel surveillance approach to link influenza variant detection with component-specific vaccine effectiveness (VE) estimation," scientists in Vancouver, Canada report. "The 2006-2007 TIV included A/NewCaledonia/20/1999( H1N1)-like, A/Wisconsin/67/2005(H3N2) like, and B/Malaysia/2506/2004(Victoria)-like components. Included participants were individuals >= 9 years of age who presented within 1 week after influenzalike illness onset to a sentinel physician between...
Source: Vaccine Weekly (2009-02-18)
|
